Compare MGRC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRC | ADPT |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | N/A | 2019 |
| Metric | MGRC | ADPT |
|---|---|---|
| Price | $110.01 | $18.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $143.00 | $16.70 |
| AVG Volume (30 Days) | 117.5K | ★ 2.0M |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $931,222,000.00 | $252,754,000.00 |
| Revenue This Year | $5.46 | $50.86 |
| Revenue Next Year | $4.31 | $0.53 |
| P/E Ratio | $18.77 | ★ N/A |
| Revenue Growth | 4.78 | ★ 42.57 |
| 52 Week Low | $94.99 | $6.26 |
| 52 Week High | $129.93 | $20.76 |
| Indicator | MGRC | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 54.89 |
| Support Level | $112.61 | $16.55 |
| Resistance Level | $118.66 | $19.42 |
| Average True Range (ATR) | 3.25 | 0.94 |
| MACD | 0.20 | 0.09 |
| Stochastic Oscillator | 31.24 | 69.48 |
McGrath RentCorp is a rental company. It is comprised of four reportable business segments namely Modular building segment (Mobile Modular); Portable storage container segment (Portable Storage); Electronic test equipment segment (TRS-RenTelco); and its classroom manufacturing business selling modular buildings used as classrooms in California (Enviroplex). The company generates its revenues majorily from the rental of its equipment on operating leases with sales of equipment occurring in the normal course of business.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).